Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: A model for the introduction of new biomarkers into clinical practice

Diagnostic Molecular Pathology

Volumn 19, Issue 4, 2010, Pages 187-193

  Farshid, Gelareh ^a   Armes, Jane E ^b   Bell, Richard ^c   Cummings, Margaret ^d   Fox, Stephen ^e   Francis, Glenn ^f   Haswell, Martin ^g   Morey, Adrienne ^h   Mccue, Glenda ⁱ   Raymond, Wendy ^j   Robbins, Peter ^k   Bilous, Michael ^l  

^a Division of Surgical Pathology   (Australia)

^b Mater Health Services   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e Andrew Love Cancer Centre   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g Roche Australia ^*  (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ WESTMEAD HOSPITAL   (Australia)

^j Woolomin Consulting   (Australia)

^k GRIBBLES PATHOLOGY   (Australia)

^l PATHWEST LABORATORY MEDICINE   (Australia)

more..

Author keywords

breast cancer; HER2 testing; in situ hybridization; national testing program; trastuzumab

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

AUSTRALIA; BREAST CANCER; BRIGHT FIELD IN SITU HYBRIDIZATION; CANCER SCREENING; CERTIFICATION; CLINICAL PRACTICE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; PARAMEDICAL EDUCATION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW;

ACCREDITATION; AUSTRALIA; BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MOLECULAR DIAGNOSTIC TECHNIQUES; PATHOLOGY, MOLECULAR; RECEPTOR, ERBB-2;

EID: 78650517326     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3181e1cc9d     Document Type: Review

References (25)

1. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648. (Pubitemid 29415219)
2. Gianni L, Goldhirsch A, Gelber RD, et al. Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer. Breast. 2009;18(suppl 1):S11.
3. Kaufman B, Mackey J, Clemens M, et al. Trastuzumab plus anastrozole prolongs progregssion-free survival in postmenopausal women with HER2-positive, hormone dependent metastatic breast cancer (MBC). Ann Oncol. 2006;17(suppl 9):abstr LBA2.
4. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol. 2005;23:4265-4274. (Pubitemid 46207001)
5. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2- positive breast cancer. J Clin Oncol. 2007;25 (18S):abstr 512.
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684. (Pubitemid 41464706)
7. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat. 2006;19:abstr 52.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
9. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet. 2007;369:29-36. (Pubitemid 46039831)
10. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
11. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854. (Pubitemid 34705057)
12. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94:855-857.
13. Francis GD, Dimech M, Giles L, et al. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: Results of the RCPA Quality Assurance Program. J Clin Pathol. 2007;60: 1277-1283. (Pubitemid 350084552)
14. Australian Government Department of Health and Ageing. Public Summary Document for Trastuzumab, powder for I.V. infusion, 150 mg, Herceptin, July 2006. Available at: Http://www.health. gov.au/internet/main/publishing.nsf/ Content/pbac-psd-trastuzumab -july06. Accessed 27 November, 2009.
15. Bilous M, Morey A, Armes J, et al. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. Pathology. 2006;38: 120-124.
16. Morey AL, Francis GD, Bilous M, et al. Comparative use of CISH and FISH to assess false-negative HER2 IHC rate. Breast Cancer Res Treat. 2006;100:(suppl 1):abstr 4007P.
17. Press MF, Finn RS, Cameron D, et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res. 2008;14:7861-7870.
18. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
19. Bokemeyer C, Bondarenko I, Hartman JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol. 2008;26:abstr 4000.
20. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672-680.
21. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
22. Langer C, Kopit J, Awad M, et al. Analysis of K-RAS mutations in patients with metastatic colorectal cancer receiving cetuximab in combination with irinotecan: Results from the EPIC trial. Ann Oncol. 2008;19:viii125-viii152.
23. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol. 2008; 26:abstr LBA4011. (Pubitemid 351461045)
24. Van Cutsem E, Lang I, D'Haens G, et al. KRAS status and efficacy in the CRYSTAL study: 1st-Lline treatment of patients with metastatic colorectal cancer (mCRC) receiving FOLFIRI with or without cetuximab. Ann Oncol. 2008;19:viii1-viii4.
25. Bilous M. HER2 testing recommendations in Australia. Pathology. 2001;33:425-427. (Pubitemid 34032945)